key: cord-0770858-7ygyi597
authors: Ita, Kevin; Ukaoma, Monica
title: COVID-19 Vaccines: New Developments and the Road Ahead
date: 2020-12-16
journal: Arch Med Res
DOI: 10.1016/j.arcmed.2020.12.009
sha: 17cc49dbd15cb3cc382f0c9adf88a1c6ca2a7b7d
doc_id: 770858
cord_uid: 7ygyi597

nan

Conflict of interest: none. Dear editor,

In a letter to the editor (published in the current issue of this journal), cost-effectiveness analysis was carried out for some Coronavirus disease 2019 (COVID-19) vaccines. The referenced analysis builds on a recent publication (1). The tragedy unleashed by (COVID-19) pandemic is mind-boggling, and a lot still needs to be done to end this public health disaster. Several research organizations are either developing or testing vaccines against COVID-19 (2). The Medicines & Healthcare Products Regulatory Agency (MHRA) in the United Kingdom has given a temporary authorization for emergency use to Pfizer and Bio-NTech for an mRNA-based vaccine (BNT162b2) against Coronavirus disease 2019 (COVID-19) (3,4). BNT162b2, encodes the SARS-CoV-2 full-length spike protein that is modified by the introduction of two proline mutations to maintain prefusion conformation and more closely mimic the intact virus (5). In the United States, no vaccine has yet been approved or authorized for use against COVID-19. The federal government, through Operation Warp Speed, has been working since the pandemic started to make one or more COVID-19 vaccines available quickly (6). On December 10, 2020, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the Center for Biologics Evaluation and Research's (CBER), will meet online to discuss Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19 in individuals 16 years of age and older (7). In a recent letter to the editor (published in the current issue of this journal), cost-effectiveness analysis was carried out for some COVID-19 vaccines. The efficacy of vaccines is normally assessed in phase 3 clinical trials to determine the proportionate reduction in disease events or predefined infection rate among vaccinated participants (8) . Efficacy is one of the components for cost-benefit analysis. Pfizer reported positive preliminary results of O90% efficacy for their RNA vaccine candidates (9) . Patients taking the BNT162b2 vaccine will require two doses of the vaccine (days 0 and 28) (10). It has been documented that vaccines bought in the USA with U.S. taxpayer dollars will be given to the American people free (6). However, providers of vaccines will charge an administration fee. This fee will be reimbursed by the patient's insurance company or by the Health Resources and Services Administration's Provider Relief Fund for uninsured patients (6). The government of the United States of America will pay Pfizer and BioNTech $1.95 billion upon the receipt of the first 100 million doses, following FDA approval or authorization (11). The U.S. government also can acquire up to an additional 500 million doses (11). Other considerations for an 'ideal' COVID-19 have been articulated: long-term storage of the vaccine at room temperature for easy transport and stockpiling, preferably a single dose as well as ease of production and scale-up (12) .

COVID-19): Current Status and Prospects for Drug and Vaccine Development

COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Challenges in evaluating SARS-CoV-2 vaccines during the COVID-19 pandemic

RNA Vaccines for COVID-19: Five Things Every Cardiologist Should Know

A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic

/$ -see front matter. Copyright Ó 2020 IMSS